Citadel Advisors - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 46 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$1,631,000
-64.2%
2,000,000
-55.6%
0.00%
-50.0%
Q4 2019$4,562,000
-24.3%
4,500,000
-35.7%
0.00%
-33.3%
Q3 2019$6,029,000
-3.3%
7,000,0000.0%0.00%0.0%
Q2 2019$6,237,000
-10.2%
7,000,0000.0%0.00%0.0%
Q1 2019$6,947,000
+14.8%
7,000,000
+16.7%
0.00%0.0%
Q3 2018$6,050,000
-55.5%
6,000,000
-61.3%
0.00%
-57.1%
Q2 2018$13,596,000
+14.4%
15,500,000
+4.7%
0.01%
+16.7%
Q1 2018$11,881,000
-26.8%
14,800,000
-27.1%
0.01%
-40.0%
Q4 2017$16,226,000
+17.2%
20,300,000
+14.0%
0.01%
-9.1%
Q3 2017$13,845,000
-70.5%
17,800,000
-63.0%
0.01%
-72.5%
Q2 2017$46,963,000
+16.7%
48,100,000
+11.6%
0.04%
+8.1%
Q1 2017$40,244,000
-8.8%
43,100,000
-12.2%
0.04%
-17.8%
Q4 2016$44,104,000
-29.6%
49,100,000
-12.3%
0.04%
-28.6%
Q3 2016$62,688,00056,000,0000.06%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2017
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders